Mirna Therapeutics (“Mirna”) announced today that Drs. Alan Venook and Steven Weitman have joined the Company’s Scientific Advisory Council (SAC) to provide guidance on the company’s clinical development program. Mirna recently achieved an industry first when its lead candidate, MRX34, became the first micro-RNA (miRNA) mimic product to enter a clinical trial in cancer.
Help employers find you! Check out all the jobs and post your resume.
